2020 Guide to Patient Support Services

Seattle Genetics

Seattle Genetics SeaGen Secure is a comprehensive reimbursement program providing personalized services to patients and helpful assistance for practices utilizing Adcetris (brentuximab vedotin) therapy.

Adcetris is a CD30-directed antibody drug conjugate indicated for several types of lymphoma (Table).


The SeaGen Secure program is available to patients who are underinsured (with commercial or government-funded insurance) and to uninsured patients.

SeaGen Secure assists in conducting a benefits investigation for each patient to determine their coverage.

For insured patients whose in­surance does not cover Adcetris, SeaGen Secure will help with their claims appeal process. Patients whose appeal is rejected may be eligible for patient assistance.


SeaGen Secure Coinsurance and Deductible Assistance Program

The Coinsurance and Deductible Assistance Program is for patients with commercial insurance who have been prescribed Adcetris. The program has some limits and caps on the amount of assistance provided by SeaGen Secure. If eligible, SeaGen Secure will send assistance to the provider on behalf of the patient. Patients may receive assistance for the duration of their therapy if they remain eligible for the program.

To be eligible for the Coinsurance and Deductible Assistance Program, patients must:

  • Have a commercial health insurance that provides coverage for Adcetris
  • Meet the program’s income requirements
  • Be permanent residents of the United States
  • Provide income and residency documentation
  • Have an FDA-approved indication for Adcetris.

SeaGen Secure Patient Assistance Program

Through the Patient Assistance Program, uninsured patients who have been prescribed Adcetris may be eligible to receive Adcetris for free. Assistance begins on a temporary 3-month period. SeaGen Secure will facilitate an alternative coverage search for the patient. Through this program, Adcetris must be ordered for each treatment cycle.

To be eligible for the Patient Assistance Program, patients must:

  • Have no insurance plan that covers the cost of Adcetris
  • Meet the program’s income requirements
  • Be permanent residents of the United States
  • Provide income and residency documentation.


To avail oneself of SeaGen Secure patient assistance and reimbursement support services, the Enrollment Form must first be completed (available at SeaGenSecure.com). Enrollment forms can be submitted electronically via the website.

Completed forms can also be faxed to 855-557-2480 or e-mailed to This email address is being protected from spambots. You need JavaScript enabled to view it.. Benefits investigation results will be faxed within 48 hours.

Prescribers are required to provide their information, provide the patient’s information and diagnosis, including an ICD-10 diagnosis code, indicate whether the patient has received a transplant and if the transplant was autologous or allogeneic, and indicate previous regimens that have been used. Patient information, including health insurance information, employer information, and gross annual family household income, must be provided.


SeaGen Secure connects patients and caregivers with an experienced Oncology Nurse Advocate. The Oncology Nurse Advocate will provide support to help address patient concerns while they are receiving treatment, and will relay important patient information to your practice.

The Oncology Nurse Advocate will work with your patient to identify concerns before they become obstacles, and offer solutions to help address specific needs; provide ongoing support throughout the treatment experience; and offer referrals to advocacy organizations for emotional support, transportation assistance, peer-to-peer connection programs, and resources for balancing work and cancer.

Patients will speak with the same Oncology Nurse Advocate every time they call SeaGen Secure.


Patient support programs

Adcetris (brentuximab vedotin)
Untreated stage III or IV classical Hodgkin lymphoma, in combination with doxorubicin, vinblastine, and dacarbazine; classical Hodgkin lymphoma ­­ at high risk for relapse or progression after autologous hematopoietic stem-cell transplant (HSCT) consolidation; classical Hodgkin lymphoma, after failure of autologous HSCT, or after ≥2 multiagent chemotherapy regimens if ineligible for transplant; untreated systemic anaplastic large-cell lymphoma or other CD30-expressing peripheral T-cell lymphoma; systemic anaplastic large-cell lymphoma after failure of ≥1 multiagent chemotherapy regimens; primary cutaneous T-cell lymphoma, or CD30-expressing mycosis fungoides after systemic therapy
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: